Efficacy Results from an Open-Label Safety Study of Galcanezumab in Patients with Episodic or Chronic Cluster Headache

被引：0
|
作者：
Gaul, C. [1 ]
Riesenberg, R. [2 ]
Stroud, C. [3 ]
Dong, Y. [3 ]
Oakes, T. Myers [3 ]
机构：
[1] Headache Ctr, Frankfurt, Germany
[2] Atlanta Ctr Med Res, Atlanta, GA USA
[3] Eli Lilly & Co, Indianapolis, IN 46285 USA
来源：
CEPHALALGIA | 2021年 / 41卷 / 1_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
AL076
引用
收藏
页码：234 / 235
页数：2
相关论文
共 50 条
  • [1] Efficacy Results from an Open-Label Safety Study of Galcanezumab in Patients with Episodic or Chronic Cluster Headache
    Gaul, C.
    Riesenberg, R.
    Stroud, C.
    Dong, Y.
    Oakes, T. Myers
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 2):
  • [2] Safety and Tolerability Findings from an Open-Label Safety Study of Galcanezumab in Patients with Episodic or Chronic Cluster Headache
    Riesenberg, R.
    Gaul, C.
    Stroud, C.
    Oakes, T. Myers
    Dong, Y.
    Bangs, M.
    Wenzel, R.
    Martinez, J.
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 2):
  • [3] Safety and Tolerability Findings from an Open-Label Safety Study of Galcanezumab in Patients with Episodic or Chronic Cluster Headache
    Riesenberg, R.
    Gaul, C.
    Stroud, C.
    Oakes, T. Myers
    Dong, Y.
    Bangs, M.
    Wenzel, R.
    Martinez, J.
    CEPHALALGIA, 2021, 41 (1_SUPPL) : 237 - 237
  • [4] Long-term open-label safety study of galcanezumab in patients with episodic or chronic cluster headache
    Riesenberg, Robert
    Gaul, Charly
    Stroud, Chad E.
    Dong, Yan
    Bangs, Mark E.
    Wenzel, Richard
    Martinez, James M.
    Oakes, Tina Myers
    CEPHALALGIA, 2022, 42 (11-12) : 1225 - 1235
  • [5] Galcanezumab treatment patterns in episodic cluster headache: findings from a Phase 3b multicenter, single-arm, open-label safety study of galcanezumab
    Andrews, J. Scott
    Rettiganti, Mallikarjuna
    Oakes, Tina
    Bardos, Jennifer
    Riesenberg, Robert
    Wenzel, Richard
    Kuruppu, Dulanji
    Martinez, James
    Kudrow, David
    CEPHALALGIA, 2019, 39 : 57 - 58
  • [6] Galcanezumab Treatment Patterns in Episodic Cluster Headache: Findings from a Phase 3b Multicenter, Single-Arm, Open-Label Safety Study of Galcanezumab
    Andrews, J.
    Rettiganti, M.
    Oakes, T. M.
    Bardos, J.
    Riesenberg, R.
    Wenzel, R.
    Kuruppu, D.
    Martinez, J.
    Kudrow, D.
    HEADACHE, 2019, 59 : 184 - 184
  • [7] Galcanezumab for episodic and chronic cluster headache
    Pohl, Heiko
    Holle-Lee, Dagny
    Broicher, Sarah D.
    Schwerdtner, Inka
    Gantenbein, Andreas R.
    Gaul, Charly
    SCHMERZ, 2023, 37 (03): : 168 - 174
  • [8] Galcanezumab in patients with episodic migraine: results from the open-label period of the phase 3 PERSIST study
    Zhou, Jiying
    Zhong, Lianmei
    Chowdhury, Debashish
    Skorobogatykh, Kirill
    Luo, Guogang
    Yang, Xiaosu
    Zhang, Mingjie
    Sun, Lingli
    Liu, Hui
    Qian, Chenxi
    Yu, Shengyuan
    JOURNAL OF HEADACHE AND PAIN, 2023, 24 (01):
  • [9] Galcanezumab in patients with episodic migraine: results from the open-label period of the phase 3 PERSIST study
    Jiying Zhou
    Lianmei Zhong
    Debashish Chowdhury
    Kirill Skorobogatykh
    Guogang Luo
    Xiaosu Yang
    Mingjie Zhang
    Lingli Sun
    Hui Liu
    Chenxi Qian
    Shengyuan Yu
    The Journal of Headache and Pain, 24
  • [10] A prospective, open-label study of milnacipran in the prevention of headache in patients with episodic or chronic migraine
    Emily Rubenstein Engel
    David Kudrow
    Alan M. Rapoport
    Neurological Sciences, 2014, 35 : 429 - 435
12345